IART INTEGRA LIFESCIENCES HOLDINGS CORP
AI brief AI-written, not reviewed by a person
Latest period figures show cash and equivalents at 252,261,000 USD for 2026-09-30, up from 214,415,000 USD at 2026-06-30 and 236,809,000 USD at 2026-03-31; stockholders’ equity stood at 1,066,617,000 USD on 2026-09-30, higher than 1,043,377,000 USD at 2026-06-30 and 1,042,406,000 USD at 2026-03-31; Diluted EPS (year) for 12 months to 2025-12-31 was -6.74 USD, versus -0.09 USD for 12 months to 2024-12-31. Revenue for the 12 months to 2025-12-31 was 1,635,245,000 USD, up slightly from 1,610,527,000 USD for 12 months to 2024-12-31; net income for 12 months to 2025-12-31 was -516,800,000 USD, a larger loss compared with -6,900,000 USD for the prior year. Observations across quarters show mixed operating cash flow and operating income with year-to-2025 driven by a sizable negative net income and negative quarterly results in certain periods, while quarterly revenue remained in the ~391–418 million USD range in 2026 through the first three quarters. filings through 10-Q and recent 8-Ks indicate ongoing quarterly updates and consolidation of the year-to-date results.
- Cash and equivalents at 2026-09-30: 252,261,000 USD; at 2026-06-30: 214,415,000 USD; at 2026-03-31: 236,809,000 USD. [1]
- Stockholders’ equity at 2026-09-30: 1,066,617,000 USD; at 2026-06-30: 1,043,377,000 USD; at 2026-03-31: 1,042,406,000 USD. [1]
- Diluted EPS (year), 12 months to 2025-12-31: -6.74 USD/shares; 12 months to 2024-12-31: -0.09 USD/shares. [1]
- Revenue (year), 12 months to 2025-12-31: 1,635,245,000 USD; 12 months to 2024-12-31: 1,610,527,000 USD. [1]
- Net income (year), 12 months to 2025-12-31: -516,800,000 USD; 12 months to 2024-12-31: -6,900,000 USD. [1]
- Operating cash flow (year), 12 months to 2025-12-31: 50,384,000 USD; 12 months to 2024-12-31: 129,382,000 USD. [1]
- Operating income (year), 12 months to 2025-12-31: -493,370,000 USD; 12 months to 2024-12-31: 28,411,000 USD. [1]
- Revenue (quarter), 3 months to 2026-09-30: 411,182,000 USD; 3 months to 2026-06-30: 418,761,000 USD; 3 months to 2026-03-31: 391,918,000 USD. [1]
- Net income (quarter), 3 months to 2026-09-30: 14,852,000 USD; 3 months to 2026-06-30: 4,482,000 USD; 3 months to 2026-03-31: -4,617,000 USD. [1]
- Total assets at 2026-09-30: 3,507,798,000 USD; at 2026-06-30: 3,563,490,000 USD; at 2026-03-31: 3,577,726,000 USD. [1]
- Total liabilities at 2026-09-30: 2,441,181,000 USD; at 2026-06-30: 2,520,113,000 USD; at 2026-03-31: 2,535,320,000 USD. [1]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
What the sources did not support
- No derived comparative figures beyond what each source states; no cross-source reconciliation of per-period values beyond the listed numbers.
- No explicit cash flow or earnings guidance; no prices, dates, or quotes beyond those provided.
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Revenue (quarter) (3 months to 2026-09-30) | 411,182,000 USD | sec-companyfacts | current | ||
| Revenue (year) (12 months to 2025-12-31) | 1,635,245,000 USD | sec-companyfacts | current | ||
| Net income (quarter) (3 months to 2026-09-30) | 14,852,000 USD | sec-companyfacts | current | ||
| Net income (year) (12 months to 2025-12-31) | -516,800,000 USD | sec-companyfacts | current | ||
| Operating income (quarter) (3 months to 2026-09-30) | 18,900,000 USD | sec-companyfacts | current | ||
| Operating income (year) (12 months to 2025-12-31) | -493,370,000 USD | sec-companyfacts | current | ||
| Diluted EPS (quarter) (3 months to 2026-09-30) | 0.19 USD/shares | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2025-12-31) | -6.74 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (quarter) (3 months to 2026-03-31) | 9,803,000 USD | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2025-12-31) | 50,384,000 USD | sec-companyfacts | current | ||
| Total assets (at 2026-09-30) | 3,507,798,000 USD | sec-companyfacts | current | ||
| Total liabilities (at 2026-09-30) | 2,441,181,000 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-09-30) | 1,066,617,000 USD | sec-companyfacts | current | ||
| Cash and equivalents (at 2026-09-30) | 252,261,000 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-10-22) | 77,800,976 shares | sec-companyfacts | current |
Context
No reviewed context has been published for IART. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add IART to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: IART.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.